New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 4, 2012
01:43 EDTVRX, ABT, GILDVertex Pharmaceuticals offers investors few catalysts, Barron's says
Vertex Pharmaceuticals (VRX) was once a Wall Street darling, but sales of its blockbuster hepatitis C drug, Incivek, are falling. And as Incivek sales keep falling, many worry that Vertex may start losing money next year. Q3 results disappointed investors. And shares sank Friday, as Goldman Sachs analyst Terence Flynn downgraded the stock to a Sell. The worry is that experimental cystic fibrosis drugs now in development may not prove to be potent enough to help patients. Also, Gilead Sciences (GILD) and Abbott Laboratories (ABT) have rival hepatitis C drugs in phase three trials, which Vertex won't start until 2014. Barron's contends that Vertex faces challenges that make the stock unattractive even at a marked-down price. Reference Link
News For VRX;ABT;GILD From The Last 14 Days
Check below for free stories on VRX;ABT;GILD the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
August 14, 2014
13:22 EDTVRXValeant, Pershing joint bid for Allergan being probed by SEC, DJ says
Subscribe for More Information
August 13, 2014
09:37 EDTGILDActive equity options trading on open
Subscribe for More Information
August 12, 2014
09:32 EDTABTAbbott says Medicare NCD expands access to MitraClip
Subscribe for More Information
August 11, 2014
17:36 EDTVRXValeant receives FTC second request under Hart-Scott-Rodino
Subscribe for More Information
12:52 EDTVRXAllergan receives second request from FTC regarding Valeant's proposal
Allergan (AGN) announced that it received a request for additional information under the Hart-Scott-Rodino Act from the U.S. Federal Trade Commission in connection with Valeant Pharmaceuticals International's (VRX) unsolicited acquisition proposal of Allergan. Allergan intends to respond fully in connection with the ongoing investigation. The Company noted that Second Request investigations typically take some time to conclude, and Allergan cannot predict how long this investigation will take or how it might otherwise develop. The company previously announced that Allerganís Board of Directors unanimously determined that Valeantís unsolicited exchange offer is grossly inadequate, substantially undervalues the company, creates significant risks and uncertainties for Allergan stockholders, and is not in the best interests of the company and its stockholders. Goldman, Sachs & Co. and BofA Merrill Lynch are serving as financial advisors to the company and Latham & Watkins, Richards, Layton & Finger, P.A. and Wachtell, Lipton, Rosen & Katz are serving as legal counsel to the company.
12:42 EDTVRXValeant shareholder ValueAct sees no need to buy Allergan, Reuters says
Subscribe for More Information
12:27 EDTVRXValueAct says Valeant does not need to buy Allergan, Reuters says
Subscribe for More Information
09:36 EDTGILDActive equity options trading on open
Subscribe for More Information
07:29 EDTGILDGilead price target raised to $110 from $90 at Argus
Subscribe for More Information
07:22 EDTVRXJudge sets hearing date for Allergan suit vs. Valeant, Reuters reports
Subscribe for More Information
August 8, 2014
17:10 EDTABT, VRXMarket finishes week up slightly as earnings offset by political events
Stocks finished the week fractionally higher than where they started as strong corporate earnings reports and better than expected economic data was weighed against concerns about geopolitical issues and negative M&A news. MACRO NEWS: A few ongoing geopolitical conflicts worried investors and weighed on shares. Russia unveiled sanctions against Western countries, banning the import of a wide range of food items from the U.S, the EU and a few allied countries in response to sanctions recently enacted against it from G7 nations... President Obama authorized the bombing of rebels in Iraq and Hamas and Israel failed to reach a permanent truce... An ISM services index, the U.S. trade deficit for June, and weekly jobless claims were all better than expected. Meanwhile, the increase in unit labor costs last quarter came in below the consensus outlook, perhaps easing fears that the Fed will need to raise interest rates sooner than expected. COMPANY NEWS: On the M&A front, two huge potential deals fell through as 21st Century Fox (FOX, FOXA) withdrew its offer to acquire Time Warner (TWX) and Sprint (S) reportedly decided to end its pursuit of a merger with peer T-Mobile (TMUS)... President Obama indicated that his administration would take unilateral steps in an effort to prevent companies from carrying out tax inversion acquisitions. Among the deals or possible transactions that involve inversion are Medtronic's (MDT) acquisition of Covidien (COV), Valeant's (VRX) proposed takeover of Allergan (AGN) and Mylan's (MYL) acquisition of Abbott's (ABT) developed markets branded generics pharmaceuticals business. Meanwhile, Walgreen's (WAG) stock tumbled after the U.S. company said it would not structure its takeover of European drugstore chain Alliance Boots as a tax inversion deal... 21st Century Fox, 3D printer maker Stratasys (SSYS), chip maker NVIDIA (NVDA), brewer Molson Coors (TAP), and luxury accessories maker Coach (COH) all rose following their earnings reports. Conversely, Target (TGT), luxury accessories maker Michael Kors (KORS) and Internet coupon provider Groupon (GRPN) fell following their results or guidance... Gannett (GCI) struck a deal to acquire the remaining 73% interest in Classified Ventures, whose primary asset is the online car shopping website Cars.com, for $1.8B from the other partners in the venture, which include McClatchy (MNI), Tribune Media (TRBAA), Graham Holdings (GHC) and A. H. Belo (AHC). Gannett also announced plans to spin-off its Publishing business, which includes USA Today, through a tax-free distribution to shareholders... McDonald's (MCD) stock was little changed after the company reported that its comparable store sales fell 2.5% in July, which was significantly worse than expected. Food quality issues weighed on the fast food company's sales in Asia and as a result of the China supplier issue, the company warned its previously issued global comparable sales forecast for 2014 is now at risk. INDEXES: The Dow finished the week up 0.35% to 16,553.93, the S&P 500 rose 0.32% to 1,931.59, and the Nasdaq gained 0.41% to 4,370.90.
10:58 EDTVRXAllergan rises after analyst sees compelling risk/reward, upgrades stock
Shares of drug maker Allergan (AGN) are rising after research firm Leerink Swann upgraded the stock in a note to investors today. WHAT'S NEW: After Allergan's stock fell recently, the shares' risk/reward ratio has become "increasingly positive" and is now compelling, Leerink analyst Seamus Fernandez wrote. Allergan's business has shown little if any weakness as a result of Valeant's (VRX) takeover bid for the company and Allergan's planned restructuring is overdue, the analyst contended. The weakness in Allergan's shares has been caused mainly by technical and arbitrage issues, according to Fernandez, who forecasts that the company can generate EPS of over $8.20 next year. Meanwhile, Valeant's bid will prevent Allergan's stock from dropping too far as long as it is on the table, Fernandez believes. Allergan has a number of other upcoming potential positive catalysts, including a potential $5B-$10B share repurchase initiative and data due to be released on August 12 on DARPin, the company's drug for wet age-related macular degeneration. A potential compelling acquisition by Allergan could also boost the stock, the analyst wrote. He upgraded the stock to Outperform from Market Perform and placed a $184 price target on the shares. PRICE ACTION: In mid-morning trading, Allergan rose $3.98, or 2.6%, to $155.67.
07:38 EDTABTAbbott overhang removed by CMS decision on MitraClip, says RBC Capital
Subscribe for More Information
07:01 EDTABT, VRXHarvard professor says Treasury can reduce inversion incentives, NY Times says
Subscribe for More Information
06:16 EDTVRXAllergan upgraded to Outperform from Market Perform at Leerink
Leerink upgraded its rating on Allergan (AGN) shares to Outperform citing a compelling risk/reward profile following the recent pullback in shares. The firm believes Valeant's (VRX) takeover attempt is having little if any impact on Allergan's business. Leerink has a $184 price target for Allergan shares, which closed yesterday down $5.18 to $151.92.
05:50 EDTVRXStocks with implied volatility movement; TWX VRX
Stocks with implied volatility movement; Time Warner (TWX) 30, Valeant (VRX) 49 according to iVolatility.
August 7, 2014
10:29 EDTABTMylan: Noise about inversion is tremendous speculation and that's all it is
Subscribe for More Information
10:20 EDTABTMylan says litigation ins ongoing in India regarding Teva
Mylan (MYL) said that it expects Teva's (TEVA) efforts to seek an injunction will "as ineffective as it was in U.S. courts." The company said it will not provide further comment on the matter. Mylan said it will also postpone its 2014 Investor Day due to the ongoing nature of the Abbott (ABT) transaction. It expects its fully realized savings and profit from new products will not be realized till 2015. Comments taken from Q2 earnings conference call.
09:36 EDTGILDActive equity options trading on open
Subscribe for More Information
06:42 EDTABT, VRXObama to look to limit inversion deals, Politico says
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use